Drug target affinity models return the endpoint on which they are trained, whereas medicinal chemistry decisions are often made with a different assay readout. Here, we trained a DeepPurpose model to estimate inhibition constants (Ki) from molecular graphs and protein sequences and asked whether those predictions could be aligned empirically with measured IC50 values without treating Ki and IC50 as interchangeable. A BindingDB-trained checkpoint retained useful cross-target ranking on the Davis kinase benchmark without Davis training data (concordance index 0.860). We then rebuilt the Ki training set from ChEMBL 37 records coded as Binding assays (assay_type = 'B'), after removing censored records and targets with poor replicate reproducibility. This reduced median fold error from 16.35x to 9.23x on a leakage-cleaned kinase panel and from 15.30x to 7.90x on a 14-target non-kinase panel before any IC50 calibration. Similarity-guided leave-one-out calibration further reduced the non-kinase panel median error to 3.12x for the original checkpoint and 3.22x for the ChEMBL checkpoint at Tanimoto T = 0.6. Because retraining removed a substantial part of the apparent correction, we interpret the calibration as a target- and chemistry-dependent empirical offset between model output and IC50 assay space, not as a mechanistic Ki-to-IC50 conversion. In a separate project-level stratification of public records, median replicate variability was 2.41x for the subset classified as biochemical Ki and 3.30x for biochemical IC50; a small-sample correction placed the Ki variability nearer 2.8x. These values provide an empirical scale for the remaining calibration error rather than a theoretical performance limit. Similarity, rather than the number of calibrators, governed the main accuracy coverage trade-off. The resulting values are surrogate IC50 estimates for cross-target triage; within-target ranking remains a limitation of the present architecture.
The comparison of adopter and non-adopter sample reveals three potential adoption inhibitor, security, data privacy, and portability, which underlines the importance of the technical and security perspectives for research investigating the adoption of technology.
Nattakarn Phaphoom, Xiaofeng Wang, S. Samuel et al.· Journal of Systems and Softw...· 111 citations· ⚡8
This study investigates how Lean internal startup facilitates software product innovation in large companies and identifies its enablers and inhibitors, and shows the potential of the method-in-action framework to investigate the Lean startup approach in non-startup context.
Henry Edison, Nina M. Smørsgård, Xiaofeng Wang et al.· Journal of Systems and Softw...· 78 citations· ⚡6
This paper highlights the challenges to conduct proper affect-related studies with psychology, provides a comprehensive literature review in affect theory, and proposes guidelines for conducting psychoempirical software engineering.
D. Graziotin, Xiaofeng Wang, P. Abrahamsson· SSE@SIGSOFT FSE· 56 citations· ⚡4
This study conducts a multiple case study on twenty European software startups and proposes a prototype-centric learning model in early stage software startups, and identifies factors that occur as barriers but also facilitators for prototyping in earlystage software startups.
Anh Nguyen-Duc, Xiaofeng Wang, P. Abrahamsson· International Conference on...· 44 citations· ⚡5
It is demonstrated that linker-free PROTACs can outperform traditional designs, marking a paradigm shift in PROTAC development for targeted protein degradation.
Pinal, a 16-billion-parameter foundation model that produces protein candidates from natural-language functional descriptions, supports natural language as a high-level interface for candidate generation in protein design, enabling programmable exploration with reduced reliance on manually specified structural or sequence constraints.
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.